Opinion|Videos|October 16, 2026
Discussion Surrounding BCMA-Targeted Options
The faculty discuss a recent exchange in Nature Reviews Clinical Oncology on the role of CAR T-cell therapy and where it fits in the treatment sequence, including concerns about toxicity and how recognition and management of these toxicities have evolved.
Advertisement
Episodes in this series
The faculty discuss a recent exchange in Nature Reviews Clinical Oncology on the role of CAR T-cell therapy and where it fits in the treatment sequence, including concerns about toxicity and how recognition and management of these toxicities have evolved. They discuss how they choose between CAR T-cell therapy and bispecific antibodies for individual patients, and how to interpret a randomized bispecific antibody study, including its patient population and limitations. The panel closes on the value of having effective BCMA-targeted options.
Advertisement
Related to this article
Erik Bengtsen, MD, explained how antidepressants may improve quality of life and how he typically works with patients who decline favorable treatment.
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose antidepressant.
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
Advertisement
Advertisement
Trending on CancerNetwork
1
VS-7375 Yields Responses in KRAS G12D–Mutated Solid Tumors
2
Personalized Cancer Vaccine Combo Is Feasible in Platinum-Sensitive Ovarian Cancer
3
Proton Therapy Tied to Less Hypothyroidism After Supraclavicular Breast RT
4
ASH Issues New Myelofibrosis Guidelines With 10 Management Recommendations
5